Balyasny Asset Management L.P. Has $20.28 Million Position in LivaNova PLC (NASDAQ:LIVN)

Balyasny Asset Management L.P. grew its holdings in LivaNova PLC (NASDAQ:LIVN) by 85.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 437,878 shares of the company’s stock after purchasing an additional 201,682 shares during the quarter. Balyasny Asset Management L.P. owned about 0.81% of LivaNova worth $20,278,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in LIVN. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after purchasing an additional 289 shares during the period. Xponance Inc. grew its holdings in LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares during the period. Mariner LLC increased its stake in LivaNova by 8.4% in the fourth quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after purchasing an additional 446 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of LivaNova by 0.6% during the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company’s stock valued at $5,158,000 after purchasing an additional 667 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN stock opened at $43.51 on Thursday. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $63.57. The stock has a market capitalization of $2.37 billion, a P/E ratio of 103.60 and a beta of 0.84. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm’s 50 day moving average is $37.79 and its 200 day moving average is $45.33.

Analysts Set New Price Targets

Several research analysts have issued reports on LIVN shares. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 25th. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Barclays decreased their price objective on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research note on Friday, March 7th. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.